Clinical Trial Update: A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs [Phase 4]

View source ↗

Summary

A phase 4 crossover trial comparing immediate-release versus extended-release torsemide on natriuretic effects over 12 hours was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Torsemide (torsemide)

Snippet

Sponsor: Sarfez Pharmaceuticals, Inc. | Conditions: Heart Failure | Phase 4 | Status: WITHDRAWN